GLP-1 and Amylin in the Treatment of Obesity

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

GLP-1 and Amylin in the Treatment of Obesity. / Jorsal, T; Rungby, J; Knop, F K; Lauritsen, Tina Vilsbøll.

I: Current Diabetes Reports, Bind 16, 1, 01.2016.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Jorsal, T, Rungby, J, Knop, FK & Lauritsen, TV 2016, 'GLP-1 and Amylin in the Treatment of Obesity', Current Diabetes Reports, bind 16, 1. https://doi.org/10.1007/s11892-015-0693-3

APA

Jorsal, T., Rungby, J., Knop, F. K., & Lauritsen, T. V. (2016). GLP-1 and Amylin in the Treatment of Obesity. Current Diabetes Reports, 16, [1]. https://doi.org/10.1007/s11892-015-0693-3

Vancouver

Jorsal T, Rungby J, Knop FK, Lauritsen TV. GLP-1 and Amylin in the Treatment of Obesity. Current Diabetes Reports. 2016 jan.;16. 1. https://doi.org/10.1007/s11892-015-0693-3

Author

Jorsal, T ; Rungby, J ; Knop, F K ; Lauritsen, Tina Vilsbøll. / GLP-1 and Amylin in the Treatment of Obesity. I: Current Diabetes Reports. 2016 ; Bind 16.

Bibtex

@article{d5126a50d3b443c191ced92229b9ceb5,
title = "GLP-1 and Amylin in the Treatment of Obesity",
abstract = "For decades, extensive research has aimed to clarify the role of pancreas and gut-derived peptide hormones in the regulation of glucose homeostasis and feeding behavior. Among these are the beta-cell hormone amylin and the intestinal L cell hormone glucagon-like peptide-1 (GLP-1). They exhibit distinct and yet several similar physiological actions including suppression of food intake, postprandial glucagon secretion, and gastric emptying-altogether lowering plasma glucose and body weight. These actions have been clinically exploited by the development of amylin and GLP-1 hormone analogs now used for treatment of diabetes and obesity. This review will outline the physiology and pharmacological potential of amylin and GLP-1, respectively, and focus on innovative peptide drug development leading to drugs acting on two or more distinct receptors, such as an amylin and GLP-1 peptide hybrid, potentially producing a more effective treatment strategy to combat the rapidly increasing global obesity.",
author = "T Jorsal and J Rungby and Knop, {F K} and Lauritsen, {Tina Vilsb{\o}ll}",
year = "2016",
month = jan,
doi = "10.1007/s11892-015-0693-3",
language = "English",
volume = "16",
journal = "Current Diabetes Reports",
issn = "1534-4827",
publisher = "Springer Healthcare",

}

RIS

TY - JOUR

T1 - GLP-1 and Amylin in the Treatment of Obesity

AU - Jorsal, T

AU - Rungby, J

AU - Knop, F K

AU - Lauritsen, Tina Vilsbøll

PY - 2016/1

Y1 - 2016/1

N2 - For decades, extensive research has aimed to clarify the role of pancreas and gut-derived peptide hormones in the regulation of glucose homeostasis and feeding behavior. Among these are the beta-cell hormone amylin and the intestinal L cell hormone glucagon-like peptide-1 (GLP-1). They exhibit distinct and yet several similar physiological actions including suppression of food intake, postprandial glucagon secretion, and gastric emptying-altogether lowering plasma glucose and body weight. These actions have been clinically exploited by the development of amylin and GLP-1 hormone analogs now used for treatment of diabetes and obesity. This review will outline the physiology and pharmacological potential of amylin and GLP-1, respectively, and focus on innovative peptide drug development leading to drugs acting on two or more distinct receptors, such as an amylin and GLP-1 peptide hybrid, potentially producing a more effective treatment strategy to combat the rapidly increasing global obesity.

AB - For decades, extensive research has aimed to clarify the role of pancreas and gut-derived peptide hormones in the regulation of glucose homeostasis and feeding behavior. Among these are the beta-cell hormone amylin and the intestinal L cell hormone glucagon-like peptide-1 (GLP-1). They exhibit distinct and yet several similar physiological actions including suppression of food intake, postprandial glucagon secretion, and gastric emptying-altogether lowering plasma glucose and body weight. These actions have been clinically exploited by the development of amylin and GLP-1 hormone analogs now used for treatment of diabetes and obesity. This review will outline the physiology and pharmacological potential of amylin and GLP-1, respectively, and focus on innovative peptide drug development leading to drugs acting on two or more distinct receptors, such as an amylin and GLP-1 peptide hybrid, potentially producing a more effective treatment strategy to combat the rapidly increasing global obesity.

U2 - 10.1007/s11892-015-0693-3

DO - 10.1007/s11892-015-0693-3

M3 - Journal article

C2 - 26699764

VL - 16

JO - Current Diabetes Reports

JF - Current Diabetes Reports

SN - 1534-4827

M1 - 1

ER -

ID: 160445236